Core Viewpoint - The document outlines the information disclosure regulations for Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2][3]. Group 1: General Provisions - The company must comply with various laws and regulations, including the Company Law and Securities Law, to ensure proper information disclosure [1]. - Information disclosure is defined as the act of publicly announcing significant information that could impact stock prices, in accordance with regulatory standards [3]. - The company and its information disclosure obligors must ensure that disclosed information is truthful, accurate, complete, and easily understandable [2][4]. Group 2: Information Disclosure Obligations - The company must disclose all information that could significantly affect stock prices or investment decisions, including major events and financial performance [9][10]. - Information disclosure must be conducted fairly, ensuring all investors have equal access to information without any selective disclosure [2][4]. - The company is required to report any major events that may not meet the legal disclosure standards but could still impact stock prices [4][9]. Group 3: Reporting Procedures - The company must follow a structured process for drafting, reviewing, and disclosing periodic reports, which include quarterly, semi-annual, and annual reports [13][14]. - Major events must be disclosed immediately, detailing the cause, current status, and potential impact on the company [28]. - The board of directors is responsible for ensuring that all disclosures are accurate and timely, with specific roles assigned to the board secretary and other management personnel [22][23]. Group 4: Internal Reporting and Compliance - The company has established internal reporting mechanisms to ensure that all significant information is communicated to the board in a timely manner [39][40]. - Directors and senior management are responsible for monitoring and reporting any significant changes in the company's operations or financial status [61][62]. - The company must maintain confidentiality regarding undisclosed information and ensure that all personnel comply with these confidentiality requirements [76][77].

General Overview - The document outlines the information disclosure management system for Jiangsu Kangwei Century Biotechnology Co., Ltd, focusing on the procedures for deferring and exempting information disclosure obligations [2][3]. Information Disclosure Deferral and Exemption - The company can defer or exempt information disclosure without applying to the Shanghai Stock Exchange if the information falls under specific conditions outlined in the listing rules [3]. - Information that involves trade secrets or confidential business information can be deferred or exempted if it meets certain criteria, such as potential harm to the company or others if disclosed [3][4]. Criteria for Deferral and Exemption - The criteria for deferring or exempting disclosure include: 1. Disclosure of core technology information that may lead to unfair competition. 2. Disclosure of operational information that could infringe on the commercial secrets of the company or third parties. 3. Other situations where disclosure could severely harm the interests of the company or others [3][4]. Responsibilities and Procedures - The company must maintain strict confidentiality regarding state secrets and cannot use the excuse of confidentiality to promote business [3][4]. - A mechanism for accountability is established for any failure to report deferral or exemption matters in a timely manner, with potential penalties for responsible individuals [4][5]. Documentation and Record-Keeping - The company is required to keep detailed records of any deferral or exemption actions, including the reasons and internal review processes, for a minimum of ten years [4][5]. - Specific forms and documentation are outlined for the approval process of deferring or exempting disclosures, including a confidentiality commitment from individuals aware of the information [5][8].

Core Viewpoint - The company has established a comprehensive compensation management system for its directors and senior management to enhance operational efficiency and ensure sustainable development [3]. Group 1: Compensation Structure - The compensation for internal directors is based on their specific roles, while external directors receive a monthly allowance without additional salary [2][3]. - Independent directors receive a monthly allowance as well, with necessary expenses for attending meetings covered by the company [2][3]. - Senior management's compensation consists of a base salary and performance bonuses linked to the company's annual performance [4]. Group 2: Compensation Management Principles - The compensation system aligns with the company's operational scale and performance [3]. - It emphasizes the integration of responsibilities, rights, and benefits, ensuring that compensation corresponds to management responsibilities [3]. - The system promotes long-term development, linking compensation to the company's sustainable growth objectives [3]. - It balances incentives and constraints, connecting overall compensation levels to assessment and reward mechanisms [3]. - Transparency and fairness are key principles in the compensation management process [3]. Group 3: Adjustment and Evaluation - Compensation for directors and senior management will be adjusted based on the company's operational performance [5]. - The company will consider industry salary trends, inflation, and individual performance when adjusting compensation [12]. - In cases of resignation or dismissal due to misconduct, compensation will be calculated based on actual tenure and performance, with potential recovery of performance-related pay [7][12]. Group 4: Implementation and Governance - The shareholders' meeting is responsible for reviewing the compensation assessment system for directors, while the board oversees senior management's compensation [4]. - The compensation and assessment committee is tasked with establishing evaluation standards and decision-making processes for compensation [4]. - The human resources and finance departments will assist in implementing the compensation plans [4].

Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has conducted its second board meeting, approving several key proposals related to its 2025 semi-annual report, fundraising, project completion, and governance changes, reflecting a commitment to transparency and operational efficiency [1][2][3]. Group 1: Financial Reporting and Fund Management - The board approved the 2025 semi-annual report, confirming compliance with relevant laws and regulations, and asserting that the report accurately reflects the company's financial status and operational results [1]. - The board also approved a special report on the storage and use of raised funds, indicating that the funds have been stored in dedicated accounts and used as intended, with no violations reported [2]. - A proposal to permanently supplement working capital with surplus funds from a completed project was approved, with 10,478.54 million yuan being reallocated for this purpose [3]. Group 2: Operational Efficiency and Governance - The company has actively implemented measures from its 2025 quality improvement and efficiency enhancement plan, focusing on core business, customer expansion, and increased R&D investment [4]. - A proposal to cancel the supervisory board and amend the company’s articles of association was approved, transferring supervisory responsibilities to the audit committee of the board [6]. - The board approved the revision and establishment of several internal governance systems to align with updated regulations and improve operational compliance [7]. Group 3: Shareholder Engagement and Future Meetings - The board proposed to hold the first extraordinary general meeting of 2025 on September 15, 2025, to discuss various matters, ensuring shareholder engagement in corporate governance [8]. - The board also approved the appointment of Yin Jianfeng as a member of the audit committee, enhancing the committee's operational capacity [9].

Core Points - The company held its second special meeting of the independent directors on August 27, 2025, with all three independent directors present [1] - The meeting was conducted in accordance with relevant laws and regulations, including the Company Law and the Management Measures for Independent Directors of Listed Companies [1] - The independent directors reviewed and approved the proposal regarding the expected daily related transactions for the year 2025, confirming that the decision-making process was legal and effective [1] Summary of Related Sections - The expected daily related transactions for 2025 are necessary for the company's normal business operations and are based on the inherent connections between the company's business and that of related parties [1] - The related transactions are conducted under principles of fairness, justice, and reasonableness, ensuring that the pricing is fair and does not harm the interests of the company or its shareholders, particularly minority shareholders [1] - The voting results for the proposal were unanimous, with all three independent directors voting in favor [2]

证券日报网讯 8月28日晚间，康为世纪发布公告称，公司第二届监事会第十四次会议审议通过了《关于 及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

格隆汇8月28日丨康为世纪(688426.SH)发布中报，2025上半年实现营业总收入8711.87万元，同比增长 29.74%；归属母公司股东净利润-5591.11万元，较上年同期亏损增加585.43万元；基本每股收益为-0.51 元。 ...

证券日报网讯 8月28日晚间，康为世纪发布公告称，公司第二届董事会第十六次会议审议通过了《关于 及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯8月28日晚间，康为世纪发布公告称，同意补选职工代表董事殷剑峰先生为公司第二届董 事会审计委员会委员。 ...

Group 1 - The company 康为世纪 (Kangwei Century) announced the second special meeting of the independent directors of its second board on August 27, 2025, which was held in a hybrid format of in-person and communication [1] - The meeting reviewed the proposal regarding the expected daily related transactions for the year 2025 [1] - For the year 2024, the company's revenue composition is entirely from the molecular diagnostics industry, accounting for 100.0% [1] Group 2 - As of the report, 康为世纪 has a market capitalization of 2.6 billion yuan [1]